Jpmorgan Chase & CO Mirum Pharmaceuticals, Inc. Transaction History
Jpmorgan Chase & CO
- $1.23 Trillion
- Q4 2024
A detailed history of Jpmorgan Chase & CO transactions in Mirum Pharmaceuticals, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 385,142 shares of MIRM stock, worth $20.2 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
385,142
Previous 27,761
1287.35%
Holding current value
$20.2 Million
Previous $1.08 Million
1371.81%
% of portfolio
0.0%
Previous 0.0%
Shares
19 transactions
Others Institutions Holding MIRM
# of Institutions
211Shares Held
53.8MCall Options Held
2.6KPut Options Held
99.7K-
Frazier Life Sciences Management, L.P. Menlo Park, CA6.57MShares$345 Million16.29% of portfolio
-
Janus Henderson Group PLC London, X04.58MShares$240 Million0.1% of portfolio
-
Black Rock Inc. New York, NY3.24MShares$170 Million0.0% of portfolio
-
Bvf Inc San Francisco, CA2.8MShares$147 Million4.33% of portfolio
-
Eventide Asset Management, LLC Boston, MA2.61MShares$137 Million2.07% of portfolio
About Mirum Pharmaceuticals, Inc.
- Ticker MIRM
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 36,751,700
- Market Cap $1.93B
- Description
- Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. The company's lead product candidate is LIVMARLI, an investigational oral drug for the treatment of progressive familial intrahepatic cholestasis disease, as well as for the trea...